Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Äèñêóññèîííûå ôîðóìû > Ðàçíîå

Ðàçíîå Ëþáûå ñîîáùåíèÿ íà ìåäèöèíñêèå òåìû, ïî êîòîðûì íåò îòäåëüíûõ ôîðóìîâ. Ôîðóì: ×àñòíàÿ ïðàêòèêà.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 24.03.2013, 15:52
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
A patients’ decisional conflict score ( improved by 6% ).

×àñòîòà "ñîìíåíèÿ â ïðàâèëüíîñòè ëå÷åíèÿ"?
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 24.03.2013, 19:06
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,694
Ïîáëàãîäàðèëè 33,378 ðàç(à) çà 31,723 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Îöåíêà "ñîìíåíèé ïàöèåíòà â ïðàâèëüíîñòè âûáîðà ëå÷åíèÿ" (â âèäå øêàëû)
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 25.03.2013, 12:30
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ìîæåò áîëüøå ê àíãèîõèðóðãàì:

In-stent late loss at 9 months in workhorse lesion subset
Workhorse lesions: (visual RVD >2.5 & <4.25mm; visual lesion length <24mm).

Åñòü óñòîé÷èâîå ðóññêîÿçû÷íîå âûðàæåíèå äëÿ ðàáî÷åé ëîøàäêè?
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 26.03.2013, 13:46
Àâàòàð äëÿ audovichenko
audovichenko audovichenko âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.01.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,477
Ïîáëàãîäàðèëè 1,531 ðàç(à) çà 1,497 ñîîáùåíèé
audovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò aberzoy Ïîñìîòðåòü ñîîáùåíèå
Ìîæåò áîëüøå ê àíãèîõèðóðãàì:

In-stent late loss at 9 months in workhorse lesion subset
Workhorse lesions: (visual RVD >2.5 & <4.25mm; visual lesion length <24mm).

Åñòü óñòîé÷èâîå ðóññêîÿçû÷íîå âûðàæåíèå äëÿ ðàáî÷åé ëîøàäêè?
Íåòó . Êñòàòè, ïåðâûé ðàç âèæó òàêîå èñïîëüçîâàíèå. Îáû÷íî workhorse - ýòî îáîçíà÷åíèå íàèáîëåå ÷àñòî èñïîëüçóåìîãî âèäà èíñòðóìåíòà.

 äàííîì ñëó÷àå, ÿ äóìàþ, èìååò ñìûñë ïåðåâåñòè êàê "íàèáîëåå ÷àñòûå".
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 26.03.2013, 16:13
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò audovichenko Ïîñìîòðåòü ñîîáùåíèå
Îáû÷íî workhorse - ýòî îáîçíà÷åíèå íàèáîëåå ÷àñòî èñïîëüçóåìîãî âèäà èíñòðóìåíòà.

 äàííîì ñëó÷àå, ÿ äóìàþ, èìååò ñìûñë ïåðåâåñòè êàê "íàèáîëåå ÷àñòûå".
Íó, ñóäÿ ïî îïðåäåëåíèþ (ðàçìåð/ïðîòÿæåííîñòü) ÿ ïîäóìàë, ÷òî âîçìîæíî ýòî êàñàåòñÿ íàèáîëåå ÷àñòûõ(?) èëè ñëîæíûõ(?) ñòåíòèðóåìûõ ïîðàæåíèé ....
Èëè ýòî òå, äëÿ êîòîðûõ õàðàêòåðíà ìèãðàöèÿ ñòåíòà?

Ñóäÿ ïî ýòîìó òåêñòó:
The PROMUS Element TM stent is the everolimus-coated member of the platinum chromium (PtCr) ElementTM Stent Series.
The Element stent delivery system is available in four stent models, each engineered for specific diameters to provide consistent stent-to-artery ratios across the range of reference vessel diameters indicated:
-
Small Vessel (SV): 2.25 mm
-
Small Workhorse (SWH): 2.50, 2.75 mm
-
Workhorse (WH): 3.00, 3.50 mm
-
Large Vessel (LV): 4.00 mm
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 26.03.2013, 18:55
Àâàòàð äëÿ Assandra
Assandra Assandra âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.08.2009
Ãîðîä: Êèåâ
Ñîîáùåíèé: 2,044
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 665 ðàç(à) çà 643 ñîîáùåíèé
Assandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò aberzoy Ïîñìîòðåòü ñîîáùåíèå
-
Small Vessel (SV): 2.25 mm
-
Small Workhorse (SWH): 2.50, 2.75 mm
-
Workhorse (WH): 3.00, 3.50 mm
-
Large Vessel (LV): 4.00 mm
Íàñêîëüêî ÿ ïîíÿëà, ýòî ïðîñòî íàèìåíîâàíèå ñòåíòîâ â çàâèñèìîñòè îò êàëèáðà ñîñóäîâ. Ìîäåëü, áðåíä. Òîãäà íå ïåðåâîäèòñÿ.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 27.03.2013, 21:31
Susanin Susanin âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 17.09.2007
Ãîðîä: Bad Segeberg, Ãåðìàíèÿ
Ñîîáùåíèé: 370
Ñêàçàë(à) ñïàñèáî: 3
Ïîáëàãîäàðèëè 50 ðàç(à) çà 50 ñîîáùåíèé
Susanin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSusanin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSusanin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSusanin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSusanin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSusanin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSusanin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSusanin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
visual RVD >2.5 & <4.25mm; visual lesion length <24mm - ýòî îêîëî 80% âñåõ ñòåíîçîâ, åñëè àíãëèéñêàÿ ôðàçåîëîãèÿ äîïóñêàåò ñëîâî Workhorse ïðèìåíèòåëüíî ê òîìó, ÍÀÄ ÷åì ìû ðàáîòàåì, à íå òîëüêî ê òîìó, ×ÅÌ ìû ðàáîòàåì, òî ÿ áû ôîðìóëèðîâàë ïðåäëîæåíèå ñ ôðàçîé "îñíîâíîé õëåá"
Àïïåíäèöèò - "îñíîâíîé õëåá" äåæóðíîãî õèðóðãà. Ïåðåëîì ëó÷à â òèïè÷íîì ìåñòå - "îñíîâíîé õëåá" âðà÷à òðàâìîïóíêòà. Ñòåíîçû ñîñóäîâ >2.5 & <4.25mm; äëèíîé <24mm - îñíîâíîé õëåá èíòåðâåíöèîííîãî êàðäèîëîãà.
Åñëè "æàíð ïðîèçâåäåíèÿ" òàêîé ïåðåâîä ïîçâîëÿåò
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 27.03.2013, 22:10
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Susanin Ïîñìîòðåòü ñîîáùåíèå
.Ñòåíîçû ñîñóäîâ >2.5 & <4.25mm; äëèíîé <24mm - îñíîâíîé õëåá èíòåðâåíöèîííîãî êàðäèîëîãà.
Åñëè "æàíð ïðîèçâåäåíèÿ" òàêîé ïåðåâîä ïîçâîëÿåò
Óâû, "æàíð" íå ïîçâîëÿåò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 27.03.2013, 22:36
AlexT AlexT âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 12.06.2003
Ãîðîä: Êðèâîé Ðîã
Ñîîáùåíèé: 861
Ïîáëàãîäàðèëè 64 ðàç(à) çà 61 ñîîáùåíèé
AlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
The first study, TAXUS PERSEUS Workhorse (A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions), will evaluate the safety and efficacy of the TAXUS Element Stent compared to Boston Scientific's first generation drug-eluting stent, the TAXUS® Express2™ Stent. This study will evaluate 1,264 patients with "workhorse" lesions from 2.75 to 4.0 millimeters. The primary endpoint of the workhorse study is target lesion failure (TLF) at 12 months, and its secondary endpoint is in-segment percent diameter stenosis at nine months.

Ñóäÿ ïî òàêîé ïîñòàíîâêå âîïðîñà ìíå êàæåòñÿ àäåêâàòíûì "íàèáîëåå ÷àñòûå"
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 28.03.2013, 16:14
Àâàòàð äëÿ Assandra
Assandra Assandra âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.08.2009
Ãîðîä: Êèåâ
Ñîîáùåíèé: 2,044
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 665 ðàç(à) çà 643 ñîîáùåíèé
Assandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAssandra ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òåïåðü åùå áîëüøå ïîõîæå íà íàèìåíîâàíèå êàëèáðà ñîñóäîâ. Ìåëêèå, êðóïíûå, à ìåæäó íèìè ïðîìåæóòî÷íûå - ðàáî÷àÿ ëîøàäêà è ëîøàäêà.
Èíòåðåñíî áû äîæäàòüñÿ ìíåíèÿ àíãèîõèðóðãîâ.

×òî êàñàåòñÿ íàèáîëåå ÷àñòûõ, ïî âñåé âèäèìîñòè - íàèáîëåå ÷àñòî ïîðàæàåìûå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 15.04.2013, 17:51
Samitin Samitin âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.08.2009
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,224
Ñêàçàë(à) ñïàñèáî: 8
Ïîáëàãîäàðèëè 765 ðàç(à) çà 691 ñîîáùåíèé
Samitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Assandra Ïîñìîòðåòü ñîîáùåíèå
Òåïåðü åùå áîëüøå ïîõîæå íà íàèìåíîâàíèå êàëèáðà ñîñóäîâ. Ìåëêèå, êðóïíûå, à ìåæäó íèìè ïðîìåæóòî÷íûå - ðàáî÷àÿ ëîøàäêà è ëîøàäêà.
È ýòî âåñüìà òî÷íî ñîâïàäàåò, ñ ïîçâîëåíèÿ ñêàçàòü, ñ äåôèíèöèåé ñ clinicaltrials.gov:
*
Öèòàòà:
The lesions are of average length in average-sized vessels ("workhorse").
([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ])
Îòâåòèòü ñ öèòèðîâàíèåì
  #12  
Ñòàðûé 11.04.2013, 18:38
Shahla Shahla âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 10.04.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 1,732
Ïîáëàãîäàðèëè 460 ðàç(à) çà 445 ñîîáùåíèé
Shahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûå êîëëåãè! Áîëüøîå ñïàñèáî çà îêàçàííóþ ïîìîùü.

Îòäåëüíûå ñëîâà ïåðåâîæó, ñìûñë íå ïîíèìàþ. Ðå÷ü èäåò î ïîêàçàíèÿõ ê ïðèìåíåíèþ íîñîâûõ êàíþëü äëÿ êèñëîðîäà:

Patients with adequate spontaneous respiratory effort, airway
protective mechanism, and tidal volume

è åùå- ventilatory drive...
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà.
Òåðàïåâò, ïóëüìîíîëîã.
Îòâåòèòü ñ öèòèðîâàíèåì
  #13  
Ñòàðûé 11.04.2013, 21:07
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
À ïîëíóþ öèòàòó (ôðàãìåíò/àáçàö) - ìîæíî?
Îòâåòèòü ñ öèòèðîâàíèåì
  #14  
Ñòàðûé 11.04.2013, 21:33
Shahla Shahla âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 10.04.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 1,732
Ïîáëàãîäàðèëè 460 ðàç(à) çà 445 ñîîáùåíèé
Shahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåShahla ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
The nasal cannula (Figure 1) is a low-flow oxygen administration system designed to add oxygen to room air when the patient inspires.
Indications:
�� Patients with adequate spontaneous respiratory effort, airway
protective mechanism, and tidal volume
�� Patients with arterial oxyhemoglobin saturation <94%
�� Patients with minimal respiratory or oxygenation problems
�� Patients who cannot tolerate a face mask


Never withhold oxygen from patients who have respiratory distress and severe hypoxemia simply because you suspect a hypoxic ventilatory drive. If oxygen administration depresses respiration, support ventilation.
Îòâåòèòü ñ öèòèðîâàíèåì
  #15  
Ñòàðûé 12.04.2013, 20:06
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âîçìîæíî ï.1
- Ïàöèåíòàì ñ àäåêâàòíûì ñàìîñòîÿòåëüíûì äûõàíèåì â êà÷åñòâå ñïîñîáà çàùèòû äûõàòåëüíûõ ïóòåé è îáåñïå÷åíèÿ àäåêâàòíîãî ïîòîêà âîçäóõà;


...

hypoxic ventilatory drive - ? ÿ ïàñ...
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 08:45.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.